EP 4313315 A1 20240207 - CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
Title (en)
CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
Title (de)
KREBSTHERAPIE MIT TOLL-LIKE-REZEPTORAGONISTEN
Title (fr)
THÉRAPIE ANTICANCÉREUSE FAISANT INTERVENIR DES AGONISTES DE RÉCEPTEURS DE TYPE TOLL
Publication
Application
Priority
- US 202163169674 P 20210401
- US 202263298589 P 20220111
- US 2022022801 W 20220331
Abstract (en)
[origin: WO2022212690A1] Embodiments of the present invention provide for methods of treating cancer and methods of delivering toll-like receptor (TLR) agonists to solid tumors in the liver using a locoregional therapy through the vasculature. In one aspect, the present invention relates to a method of treating primary liver cancers such as hepatocellular carcinoma (HCC) and intra- hepatic cholangiocarcinoma (ICC) comprising administering TLR9 agonists to the liver.
IPC 8 full level
A61P 35/00 (2006.01); A61P 1/16 (2006.01)
CPC (source: EP KR)
A61K 31/7088 (2013.01 - EP KR); A61K 48/00 (2013.01 - KR); A61P 1/16 (2018.01 - EP); A61P 35/00 (2018.01 - EP KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022212690 A1 20221006; AU 2022249092 A1 20231012; AU 2022249092 A9 20231026; CA 3215582 A1 20221006; DE 112022001882 T5 20240118; DE 112022001882 T9 20240229; EP 4313315 A1 20240207; JP 2024512765 A 20240319; KR 20240004419 A 20240111
DOCDB simple family (application)
US 2022022801 W 20220331; AU 2022249092 A 20220331; CA 3215582 A 20220331; DE 112022001882 T 20220331; EP 22782201 A 20220331; JP 2023560819 A 20220331; KR 20237037584 A 20220331